GBI Research’s analysis suggests that small and medium biopharmaceutical companies will form strategic partnerships with pharmaceutical and biotechnology companies to deliver synergy, innovation, and high value business transactions despite being faced by a challenging market environment, uncertain competitive positioning, and unstructured funding options. The Small and Medium Enterprises (SMEs) contribute to the majority of biopharmaceutical research and development programs indicating the strength of the biopharmaceutical SME pipeline. Big pharmaceutical companies are facing challenges such as the patent expiry of blockbuster drugs and low R&D productivity. These two factors will be the prime factors driving partnerships between biopharmaceutical SMEs and bigger companies in the pharmaceutical and biotechnology industries. These partnerships are a win-win situation for both parties. This is because the biotechnology SMEs are faced with a challenging market due to the lack of internal commercialization skills and other management skills which make them ill equipped to compete with bigger players in a strict regulatory environment. In addition, the SMEs have access to fragmented funding which depends on multiple sources and factors.
Â
For more information, please click or add the below link to your browser:
Â
The importance of SMEs in driving innovation in the industry will encourage an increased number of Mergers & Acquisitions (M&As) involving biopharmaceutical and biotechnology SMEs. The small biotechnology companies are highly focused on fulfilling the unmet need in the market. This helps SMEs to attract funding from different sources and also compete with bigger players.
GBI Research’s analysis suggests that research intensive biopharmaceutical and biotechnology SMEs will contribute to the innovative pipeline of pharmaceutical and biotechnology companies through licensing agreements and research collaborations. Biotechnology SMEs focus primarily on research and development activities. The biotechnology SMEs play an important role in the industry by enhancing the product pipeline of the industry through their innovative ideas and products. SMEs have very few commercialized products and are valued based on the potential of their products in the pipeline. Almost all the resources and employees in a biotechnology SME are dedicated to research and development. In addition, the close association of SMEs with academic research enhances the innovative potential of the sector. Many of the biotechnology SMEs have been established as spin-offs from university research departments. GBI Research’s study of more than 3,000 pipeline products revealed that biotechnology SMEs account for more than 87% of the biotechnology pipeline. This indicates that a majority of the new compounds under development in the biotechnology industry belong to SMEs.
Â
For more information, please click or add the below link to your browser:
Â
GBI Research, the leading business intelligence provider, has released its latest research, “Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotech Clusters, Funding Characteristics and Regulatory Landscapeâ€. The report provides an overview of the small and medium biopharmaceutical enterprises in the North American and European regions. The report provides an insight into the importance of Small and Medium Enterprises (SMEs) in the biotechnology industry. It covers market characterization, the geographical spread of SMEs, drivers and restraints, regulatory scenarios, and funding challenges faced by the biotechnology SME industry. The study reviews the role of SMEs in driving the pipeline within the biotechnology industry, the role of governments in promoting the sector, as well as potential gaps. It provides a comprehensive analysis of the deals in the SME sector and also provides competitive benchmarking to understand how SMEs compete.
Â
For more information, please click or add the below link to your browser:
Â
Or visit our report store: http://www.globalbusinessintelligence.com
